What is the share price of Dr. Lal PathLabs Ltd (LALPATHLAB) today?
The share price of LALPATHLAB as on 30th October 2026 is ₹1906.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Dr. Lal PathLabs Ltd (LALPATHLAB) share?
The past returns of Dr. Lal PathLabs Ltd (LALPATHLAB) share are- Past 1 week: 3.75%
- Past 1 month: -1.52%
- Past 3 months: 1.47%
- Past 6 months: 39.44%
- Past 1 year: 23.42%
- Past 3 years: 61.32%
- Past 5 years: 4.43%
What are the peers or stocks similar to Dr. Lal PathLabs Ltd (LALPATHLAB)?
The peers or stocks similar to Dr. Lal PathLabs Ltd (LALPATHLAB) include:What is the dividend yield % of Dr. Lal PathLabs Ltd (LALPATHLAB) share?
The current dividend yield of Dr. Lal PathLabs Ltd (LALPATHLAB) is 1.08.What is the market cap of Dr. Lal PathLabs Ltd (LALPATHLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dr. Lal PathLabs Ltd (LALPATHLAB) is ₹31866.80 Cr as of 30th October 2026.What is the 52 week high and low of Dr. Lal PathLabs Ltd (LALPATHLAB) share?
The 52-week high of Dr. Lal PathLabs Ltd (LALPATHLAB) is ₹2038.60 and the 52-week low is ₹1272.60.What is the PE and PB ratio of Dr. Lal PathLabs Ltd (LALPATHLAB) stock?
The P/E (price-to-earnings) ratio of Dr. Lal PathLabs Ltd (LALPATHLAB) is 63.13. The P/B (price-to-book) ratio is 12.54.Which sector does Dr. Lal PathLabs Ltd (LALPATHLAB) belong to?
Dr. Lal PathLabs Ltd (LALPATHLAB) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Dr. Lal PathLabs Ltd (LALPATHLAB) shares?
You can directly buy Dr. Lal PathLabs Ltd (LALPATHLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Dr. Lal PathLabs Ltd
LALPATHLAB Share Price
NSE₹1,906.400.28% (-5.30)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP
LALPATHLAB Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
LALPATHLAB Performance & Key Metrics
LALPATHLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 58.81 | 12.54 | 1.08% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.81 | 5.76 | 0.50% |
81%
Analysts have suggested that investors can buy this stock
from 26 analysts
Price Upside
Earnings Growth
Rev. Growth
LALPATHLAB Company Profile
Dr Lal Pathlabs Private Limited is headquartered in Gurgaon, Haryana, India and is a medical laboratory operator.
APOLLOHOSP
PE Ratio
62.56
62.56
1Y Return
8.45%
8.45%
Buy Reco %
86.67
86.67
MANIPALHOS
PE Ratio
98.64
98.64
1Y Return
0.33%
0.33%
Buy Reco %
66.67
66.67
MAXHEALTH
PE Ratio
58.03
58.03
1Y Return
27.03%
27.03%
Buy Reco %
84.00
84.00
PE Ratio
152.80
152.80
1Y Return
2.36%
2.36%
Buy Reco %
91.67
91.67
FORTIS
PE Ratio
55.67
55.67
1Y Return
26.46%
26.46%
Buy Reco %
90.00
90.00
LALPATHLAB Sentiment Analysis
LALPATHLAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
LALPATHLAB Stock Summary · July 2026
Management struck a largely upbeat tone, saying the quarter combined the fastest revenue growth in four years with solid earnings expansion. Revenue rose 19.1% year over year to Rs. 798 crore, while EBITDA increased 28.7% to Rs. 247 crore and the EBITDA margin expanded to 31.0%. Growth was supported by higher patient volumes, which ran at around 8% and were ahead of the earlier 6%–7% full-year expectation, as well as better realization from mix improvements and the ongoing CGHS and ECHS pricing benefit, estimated at about 2%–3%. Management emphasised broad-based operational momentum, scientific leadership and patient experience as core priorities, citing 116 new test launches, including four first-in-India tests, faster turnaround times, a GenAI-enabled WhatsApp bot and rural outreach that tested more than 110,000 patients across seven states. At the same time, management noted that quarterly trends can be uneven and said a clearer read on full-year volume growth should emerge after Q2 and the first half, while additional pricing action would depend on competition and cost pressures.
LALPATHLAB Stock Growth Drivers
LALPATHLAB Stock Growth Drivers
1Healthy Balance Sheet and Shareholder Returns
Financial strength remained a clear positive, with the company ending the quarter with net cash
LALPATHLAB Stock Challenges
LALPATHLAB Stock Challenges
2Limited International Expansion
The company’s international business remains a very small contributor, staying below 5% of revenue, and
Persistently High Industry Competition
Competitive pressure in the diagnostics industry remains elevated and management is not expecting meaningful relief.
LALPATHLAB Forecast
LALPATHLAB Forecasts
Price
Revenue
Earnings
LALPATHLAB Share Price Forecast
LALPATHLAB Share Price Forecast
2026
Current
₹1,906.40
Baseline
Forecast for Oct 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹1,906.40
Baseline
Forecast for Oct 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
LALPATHLAB Company Revenue Forecast
LALPATHLAB Company Revenue Forecast
2026
Current
₹2.86
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹2.86
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
LALPATHLAB Stock EPS (Earnings Per Share) Forecast
LALPATHLAB Stock EPS (Earnings Per Share) Forecast
2026
Current
₹30.16
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹30.16
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
LALPATHLAB
LALPATHLAB
Income
Balance Sheet
Cash Flow
Quarterly Normal View
LALPATHLAB Income Statement
LALPATHLAB Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 563.80 | 622.50 | 682.10 | 621.80 | 628.40 | 697.90 | 755.40 | 684.20 | 726.70 | 829.60 | ||||||||||
Operating & Other expenses | 400.70 | 431.90 | 457.70 | 442.70 | 433.60 | 477.50 | 506.50 | 510.60 | 515.90 | 550.20 | ||||||||||
EBITDA | 163.10 | 190.60 | 224.40 | 179.10 | 194.80 | 220.40 | 248.90 | 173.60 | 210.80 | 279.40 | ||||||||||
| Depreciation/Amortization | 36.60 | 34.70 | 35.30 | 35.50 | 36.40 | 34.60 | 40.50 | 42.10 | 44.60 | 44.40 | ||||||||||
| PBIT | 126.50 | 155.90 | 189.10 | 143.60 | 158.40 | 185.80 | 208.40 | 131.50 | 166.20 | 235.00 | ||||||||||
| Interest & Other Items | 6.60 | 6.00 | 6.00 | 5.30 | 5.00 | 4.70 | 4.80 | 7.20 | 6.10 | 6.30 | ||||||||||
| PBT | 119.90 | 149.90 | 183.10 | 138.30 | 153.40 | 181.10 | 203.60 | 124.30 | 160.10 | 228.70 | ||||||||||
| Taxes & Other Items | 35.40 | 43.50 | 53.90 | 41.60 | -1.40 | 48.70 | 53.00 | 33.80 | 28.80 | 59.20 | ||||||||||
| Net Income | 84.50 | 106.40 | 129.20 | 96.70 | 154.80 | 132.40 | 150.60 | 90.50 | 131.30 | 169.50 | ||||||||||
| EPS | 5.07 | 6.40 | 7.76 | 5.80 | 9.29 | 7.94 | 9.03 | 5.42 | 7.86 | 10.15 |
LALPATHLAB Company Updates
FY 2027FY 2027
Investor Presentation
Jul 24PDF
LALPATHLAB Stock Peers
LALPATHLAB Past Performance & Peer Comparison
LALPATHLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHospitals & Diagnostic Centres
Compare valuation on Screener
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Dr. Lal PathLabs Ltd | 63.13 | 12.54 | 1.08% |
| Apollo Hospitals Enterprise Limited | 62.56 | 12.17 | 0.24% |
| Manipal Health Enterprises Limited | 98.64 | 10.00 | — |
| Max Healthcare Institute Limited | 58.03 | 7.79 | 0.23% |
Compare valuation on ScreenerLALPATHLAB Stock Price Comparison
Compare LALPATHLAB with any stock or ETFCompare LALPATHLAB with any stock or ETF
LALPATHLAB
LALPATHLAB Holdings
LALPATHLAB Shareholdings
LALPATHLAB Promoter Holdings Trend
LALPATHLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
LALPATHLAB Institutional Holdings Trend
LALPATHLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has increased by 1.39%
LALPATHLAB Shareholding Pattern
LALPATHLAB Shareholding Pattern
LALPATHLAB Shareholding History
LALPATHLAB Shareholding History
Foreign Institutions
Mutual Funds Invested in LALPATHLAB
Mutual Funds Invested in LALPATHLAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding Dr. Lal PathLabs Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.6054% | Percentage of the fund’s portfolio invested in the stock 0.76% | Change in the portfolio weight of the stock over the last 3 months 0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 46/89 (-20) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.5687% | Percentage of the fund’s portfolio invested in the stock 2.22% | Change in the portfolio weight of the stock over the last 3 months 0.37% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 6/66 (+3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.4653% | Percentage of the fund’s portfolio invested in the stock 1.67% | Change in the portfolio weight of the stock over the last 3 months 0.54% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 55/95 (+8) |
Compare 3-month MF holding change on Screener
smallcases containing LALPATHLAB stock
smallcases containing LALPATHLAB stock
Looks like this stock is not in any smallcase yet.
LALPATHLAB Events
LALPATHLAB Events
LALPATHLAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
LALPATHLAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.08%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹10.78 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
LALPATHLAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
LALPATHLAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.08%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹10.78 every year
LALPATHLAB Upcoming Dividends
LALPATHLAB Upcoming Dividends
No upcoming dividends are available
LALPATHLAB Past Dividends
LALPATHLAB Past Dividends
Cash Dividend
Ex DateEx DateJul 30, 2026
Interim
Interim | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Jul 30, 2026
Cash Dividend
Ex DateEx DateJun 25, 2026
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Jun 25, 2026
Cash Dividend
Ex DateEx DateFeb 5, 2026
Interim 3
Interim 3 | Div/Share: ₹3.50
Dividend/Share
₹3.50
Ex DateEx Date
Feb 5, 2026
Cash Dividend
Ex DateEx DateNov 7, 2025
Interim 2
Interim 2 | Div/Share: ₹7.00
Dividend/Share
₹7.00
Ex DateEx Date
Nov 7, 2025
Cash Dividend
Ex DateEx DateAug 6, 2025
Interim
Interim | Div/Share: ₹6.00
Dividend/Share
₹6.00
Ex DateEx Date
Aug 6, 2025
LALPATHLAB Stock News & Opinions
LALPATHLAB Stock News & Opinions
Articles & Videos
Corporate
Corporate
Dr. Lal PathLabs to review potential interim dividend at November board meetingDr. Lal PathLabs Limited will consider a second interim dividend, if any, on its equity shares for the financial year 2026-27 at a board meeting scheduled for November 04, 2026, alongside the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
4 days agoCapital Market - Live
Corporate
Corporate
Dr. Lal PathLabs to review potential interim dividend at November board meetingDr. Lal PathLabs Limited will consider a second interim dividend, if any, on its equity shares for the financial year 2026-27 at a board meeting scheduled for November 04, 2026, alongside the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
4 days agoCapital Market - Live
Corporate
Corporate
PathLabs Unifiers Private Limited completes acquisition of Centra path Labs Private LimitedDr. Lal PathLabs Limited announced that its wholly-owned subsidiary, PathLabs Unifiers Private Limited, has acquired the remaining 30% equity stake in Centra path Labs Private Limited, a subsidiary of PUPL, on October 13, 2026, making CPL a wholly-owned subsidiary. The acquisition involved a cash consideration of Rs 1608.352 per share, with Centra path Labs Private Limited reporting a turnover of Rs 20.5 crore in fiscal year 2026, Rs 23.7 crore in fiscal year 2025, and Rs 20.8 crore in fiscal year 2024.
2 weeks agoCapital Market - Live
Corporate
Corporate
Dr. Lal PathLabs invests to acquire remaining stake in CentraPath Labs for up to Rs 30.3 croreDr. Lal PathLabs Limited has made a further investment in its wholly owned subsidiary, PathLabs Unifiers Private Limited, by subscribing to its equity shares on October 12, 2026, to fund the acquisition of the remaining 30% equity stake in CentraPath Labs Private Limited, another subsidiary of PathLabs Unifiers Private Limited, which will then become wholly owned. The cash consideration for the investment will not exceed Rs 30.3 crore.
2 weeks agoCapital Market - Live
Corporate
Corporate
Dr. Lal PathLabs acquires stake in SN Genelab Private Limited, effective October 1, 2026Dr. Lal PathLabs Limited has completed the acquisition of a stake in SN Genelab Private Limited on October 1, 2026, according to a regulatory filing with the National Stock Exchange of India Limited and BSE Limited, following prior board approval announced on September 24, 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Dr. Lal PathLabs acquired an 80% stake in Sunshine Healthcare Limited in GhanaDr. Lal PathLabs FZCO, a wholly-owned subsidiary of Dr. Lal PathLabs Limited, has completed the acquisition of an 80% stake in Sunshine Healthcare Limited (“SHL”) in Ghana, according to a regulatory filing on September 26, 2026, following prior approval on July 24, 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Dr. Lal PathLabs to review quarterly results at board meeting November 4, 2026Dr. Lal PathLabs Limited will hold a board meeting on Wednesday, November 04, 2026, to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ending September 30, 2026, the company said in a filing. The trading window for dealing in securities of Dr. Lal PathLabs Limited will be closed from October 1, 2026, to November 06, 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Dr. Lal PathLabs to review quarterly results at board meeting November 4, 2026Dr. Lal PathLabs Limited will hold a board meeting on Wednesday, November 04, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ending September 30, 2026, according to a regulatory filing. The company’s trading window for securities will be closed from October 1, 2026, to November 06, 2026, in accordance with SEBI regulations.
1 month agoCapital Market - Live
Corporate
Corporate
Dr. Lal PathLabs to acquire 70% stake in SN Genelab for up to Rs 168 croreDr. Lal PathLabs Limited announced that its board approved the acquisition of a 70% stake in SN Genelab Private Limited (“SN Gene”) from existing shareholders for a cash consideration of up to Rs 168 crore plus a performance-linked earn-out capped at Rs 31.5 crore, with the transaction expected to be completed by November 30, 2026; SN Gene, incorporated on December 16, 2013, reported a turnover of Rs 57.96 crore for fiscal year 2026, Rs 53.36 crore for fiscal year 2025, and Rs 43.27 crore for fiscal year 2024, and is engaged in providing Diagnostics - Genomics services.
1 month agoCapital Market - Live
Corporate
Corporate
Dr. Lal PathLabs to acquire 70% stake in SN Genelab for up to Rs 168 croreDr. Lal PathLabs Limited announced that its board approved the acquisition of a 70% stake in SN Genelab Private Limited (“SN Gene”) from existing shareholders for a cash consideration of up to Rs 168 crore plus a performance-linked earn-out capped at Rs 31.5 crore, with the transaction expected to be completed by November 30, 2026; SN Gene, incorporated on December 16, 2013, reported a turnover of Rs 57.96 crore for fiscal year 2026, Rs 53.36 crore for fiscal year 2025, and Rs 43.27 crore for fiscal year 2024, and is engaged in providing Diagnostics - Genomics services.
1 month agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 11.9%, vs industry avg of 17.91%
Over the last 5 years, market share decreased from 3.71% to 2.74%
Over the last 5 years, net income has grown at a yearly rate of 11.6%, vs industry avg of 62.46%